...
首页> 外文期刊>Cytotherapy >Cord blood collection and processing with hydroxyethyl starch or non-hydroxyethyl starch
【24h】

Cord blood collection and processing with hydroxyethyl starch or non-hydroxyethyl starch

机译:用羟乙基淀粉或非羟乙基淀粉收集和处理脐带血

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Collection and processing characteristics influencing quality of cord blood (CB) units play an essential role to cord blood banks (CBBs). At many CBBs, volume reduction is performed using hydroxyethyl starch (HES) and the Sepax (Biosafe) automated cell processing system. Due to the withdrawal of HES from the European market, a validation of the nonHES protocol was performed. Methods. This partially retrospective study identified CB characteristics such as gestational age and CB volume/cell count correlated with higher quality. For the nonHES validation, CB was analyzed for total nucleated cell (TNC), mononuclear cell (MNC) recovery, hematocrit (HCT) and colony-forming units (CFUs). Viabilities of CD34(+) and CD45(+) cells were determined by 7-aminoactinomycin D (7-AAD) and AnnexinV (AnnV) staining and compared for 21 mL and 42 mL buffy coat (BC) samples applying the HESonHES protocol. Results. Factors affecting the potency of CB transplants were the gestational age and the volume reduction to a defined BC volume. High initial cell counts and CB volumes correlated negatively with post-processing TNC recovery for lower BC volumes. Post-processing HES and nonHES results were comparable, but nonHES revealed a significantly lower post-thaw recovery of viable CD34+ cells measured by 7-AAD/AnnV (21 mL: 45.4 +/- 16.4%; 42 mL: 67.3 +/- 14.5%) as compared with HES (21 mL: 72.7 +/- 14.4%, P = 0.0164; 42 mL: 83.4 +/- 14.7%, P = 0.0203). Discussion. Due to the lower post-thaw CD34(+) cell viability (AnnV(-)/7-AAD(-)) for nonHES samples, the use of HES is recommended, ideally combined with a high BC volume. The post-processing HCT has no statistically significant impact on the post-thaw CD34(+) cell viability (AnnV(-)/7-AAD(-)).
机译:背景。影响脐带血(CB)单元质量的采集和加工特性对脐带血库(CBB)至关重要。在许多CBB上,使用羟乙基淀粉(HES)和Sepax(Biosafe)自动化细胞处理系统进行体积减小。由于HES从欧洲市场撤出,因此对nonHES协议进行了验证。方法。这项部分回顾性研究确定了CB特征,例如胎龄和CB体积/细胞数量与更高的质量相关。对于nonHES验证,分析了CB的总有核细胞(TNC),单核细胞(MNC)回收率,血细胞比容(HCT)和集落形成单位(CFU)。通过7-氨基放线菌素D(7-AAD)和AnnexinV(AnnV)染色确定CD34(+)和CD45(+)细胞的活力,并应用HES / nonHES方案比较21 mL和42 mL血沉棕黄层(BC)样品。结果。影响CB移植效力的因素是胎龄和将体积缩小至确定的BC体积。高初始细胞数和CB量与较低BC量的后处理TNC回收率呈负相关。处理后的HES和nonHES结果相当,但nonHES显示通过7-AAD / AnnV测定的CD34 +细胞的融化后回收​​率显着降低(21 mL:45.4 +/- 16.4%; 42 mL:67.3 +/- 14.5与HES(21 mL:72.7 +/- 14.4%,P = 0.0164; 42 mL:83.4 +/- 14.7%,P = 0.0203)。讨论。由于非HES样品的融化后CD34(+)细胞活力较低(AnnV(-)/ 7-AAD(-)),因此建议使用HES,理想情况下应与高BC量结合使用。后处理的HCT对融化后的CD34(+)细胞活力(AnnV(-)/ 7-AAD(-))没有统计学上的显着影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号